Pierret, A
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, et al
For Korner, whats particularly worrying when it comes to microdosing is the lack of research, given that these medications carry proven cardiovascular and kidney benefits that have never been evaluated at microdose levels
Conclusions In this study, we present a robust and integrative virtual screening strategy for the identification of agonists of the GLP-1R
3 thng mi t c cho l mc kh l an ton, va t mc ch nui dng da v khng gy hi cho c th ni chung
These molecules were tested for DPP-4 inhibitory activity, with 6-methyl-5-(4-methylpyridin-2-yl)-1-phenyl-1H-pyrazolo[3,4-d] pyrimidin-4(5H)-one (compound 29) (Figure 5) showing the highest activity (IC 50 = 1.06 M)